Go Pro
→ American retirees will miss THIS. Big Banks just moved in. (From Cedar Gold Group) (Ad)tc pixel Free ALP Stock Alerts

Trading of Portage Biotech was halted at 12:22 PM EST due to "LULD Pause".

Portage Biotech (ALP) Financials

Portage Biotech logo
$3.72 -1.69 (-31.24%)
As of 03:45 PM Eastern
Compare
Annual Income Statements for Portage Biotech

Annual Income Statements for Portage Biotech

This table shows Portage Biotech's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 3/31/2016 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2022 3/31/2023 3/31/2024 3/31/2024 3/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -5.71 41 99 -2.59 -4.46 -17 -110 -75 -75 -6.77 -39
Consolidated Net Income / (Loss)		 -9.20 -0.64 124 -3.59 -7.25 -19 -105 -75 -75 -7.81 -20
Net Income / (Loss) Continuing Operations		 -9.20 -1.13 124 -3.59 -7.25 -19 -105 -72 -72 -7.81 -20
Total Pre-Tax Income 		-9.20 -1.13 124 -3.59 -6.51 -15 -123 -86 -86 -6.78 -39
Total Operating Income		 -9.20 -35 -2.24 -2.76 -5.98 -16 -17 -18 -18 -7.42 -23
Total Gross Profit		 0.00 -0.49 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.49 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 9.19 35 2.24 2.76 5.98 16 17 18 18 7.38 23
Selling, General & Admin Expense		 4.01 1.92 1.45 0.86 1.87 8.82 7.90 5.66 5.66 4.25 20
Research & Development Expense		 4.58 32 0.79 1.91 4.11 6.77 8.67 13 13 3.13 2.80
Total Other Income / (Expense), net		 0.00 35 126 -0.83 -0.53 0.77 -106 -64 -64 -0.40 2.88
Other Income / (Expense), net		 0.00 35 126 -0.85 0.02 0.81 -106 -65 -64 -0.40 2.88
Income Tax Expense		 - - 0.00 0.00 0.74 4.35 -18 -11 -11 -0.00 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest		 -3.49 -17 0.00 -0.96 -1.92 2.30 0.11 0.04 0.04 0.01 0.00
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - -25 25 -0.05 -0.88 0.00 5.28 0.04 0.04 0.00 0.00
Basic Earnings per Share		 ($0.02) $0.06 $46.21 ($0.55) ($0.49) ($1.29) ($6.49) ($77.83) ($77.83) ($5.72) ($4.18)
Weighted Average Basic Shares Outstanding		 - 254.05K 2.68M 4.82M 10.95K 13.06M 16.12M 968K 968K - 23.47M
Diluted Earnings per Share		 ($0.02) $0.06 $45.89 ($0.55) ($0.49) ($1.29) ($6.49) ($77.83) ($77.83) ($5.72) ($4.18)
Weighted Average Diluted Shares Outstanding		 - 272.19K 2.70M 4.82M 10.95K 13.06M 16.12M 968K 968K - 23.47M
Weighted Average Basic & Diluted Shares Outstanding		 - - 280.72M 4.82M 10.95K 11.73M 32.24M 806K - - 23.47M

Quarterly Income Statements for Portage Biotech

No quarterly income statements for Portage Biotech are available.

Annual Cash Flow Statements for Portage Biotech

This table details how cash moves in and out of Portage Biotech's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 3/31/2016 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2022 3/31/2023 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Net Change in Cash & Equivalents		 2.97 14 7.36 -1.35 -7.77 21 -124 -126 -92 -3.62 -3.00
Net Cash From Operating Activities		 -5.84 14 -1.07 -0.86 -7.47 -8.51 -124 -126 -95 -5.77 -18
Net Cash From Continuing Operating Activities		 -5.84 14 -1.08 -1.04 -7.47 -8.51 -124 -126 -95 -5.77 -18
Net Income / (Loss) Continuing Operations		 -5.71 -0.64 124 -3.59 -7.25 -19 -105 -105 -75 -6.78 -39
Consolidated Net Income / (Loss)		 -5.71 -0.64 124 -3.59 -7.25 -19 -105 -105 -75 -6.78 -39
Depreciation Expense		 - - - - - 0.00 0.00 0.00 0.05 0.04 0.19
Non-Cash Adjustments To Reconcile Net Income		 0.00 15 -125 2.19 0.75 8.33 -1.23 -1.23 8.74 0.58 20
Changes in Operating Assets and Liabilities, net		 -0.14 - 0.02 0.36 -1.24 2.33 -18 -21 -29 0.39 0.42
Net Cash From Investing Activities		 -1.70 0.00 5.66 -0.45 0.00 0.00 0.00 0.00 2.81 0.00 -1.04
Net Cash From Continuing Investing Activities		 -1.70 0.00 6.61 -0.69 0.00 0.00 0.00 0.00 2.81 0.00 -1.04
Purchase of Property, Plant & Equipment		 - - -0.68 -0.69 - - - - - - -1.04
Net Cash From Financing Activities		 11 0.00 2.78 -0.05 -0.30 29 0.00 0.00 0.68 2.15 16
Net Cash From Continuing Financing Activities		 11 0.00 2.73 0.00 -0.30 29 0.00 0.00 0.68 2.15 16
Issuance of Common Equity		 11 - - - - 29 - - 0.68 2.15 16
Cash Interest Paid		 - - - - 0.00 0.02 0.00 0.00 0.03 0.00 0.05

Quarterly Cash Flow Statements for Portage Biotech

No quarterly cash flow statements for Portage Biotech are available.

Annual Balance Sheets for Portage Biotech

This table presents Portage Biotech's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2025 2026
Period end date 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Total Assets		 60 10 174 173 175 99 7.78 2.23 20
Total Current Assets		 59 7.62 6.55 3.79 4.95 14 7.70 2.23 4.00
Cash & Equivalents		 0.16 7.52 6.17 3.15 2.77 11 5.03 1.67 0.49
Prepaid Expenses		 0.06 0.04 0.28 0.57 2.18 2.69 - 0.56 1.98
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.77 2.44 167 169 170 85 0.08 0.00 16
Other Noncurrent Operating Assets		 - 0.74 119 119 119 0.88 0.08 0.00 5.02
Total Liabilities & Shareholders' Equity		 60 10 174 173 175 99 7.78 2.23 20
Total Liabilities		 0.31 0.38 25 28 27 24 4.45 3.05 13
Total Current Liabilities		 0.11 0.15 1.79 2.57 3.21 1.87 2.88 1.10 13
Accounts Payable		 0.11 0.13 1.11 1.27 1.94 1.87 2.84 1.10 4.15
Other Current Liabilities		 - - - - - 0.00 0.04 0.00 0.07
Total Noncurrent Liabilities		 0.20 0.23 23 25 24 22 1.57 1.95 0.27
Capital Lease Obligations		 - - - - - 0.00 0.01 0.00 0.07
Other Noncurrent Operating Liabilities		 - 0.02 0.02 1.00 1.12 11 1.56 1.95 0.19
Total Equity & Noncontrolling Interests		 60 9.62 149 146 148 75 3.33 -0.83 6.52
Total Preferred & Common Equity		 60 9.62 100 97 101 76 4.02 -0.12 7.23
Total Common Equity		 60 9.62 100 97 101 76 4.02 -0.12 7.23
Common Stock		 18 24 116 118 131 219 219 222 266
Retained Earnings		 15 -14 -17 -22 -38 -160 -239 -245 -284
Treasury Stock		 - - - - - - - 0.00 -0.02
Other Equity Adjustments		 1.71 0.27 0.32 0.06 7.98 21 24 24 25
Noncontrolling Interest		 - 0.00 49 49 46 -0.65 -0.69 -0.70 -0.71

Quarterly Balance Sheets for Portage Biotech

No quarterly balance sheets for Portage Biotech are available.

Annual Metrics And Ratios for Portage Biotech

This table displays calculated financial ratios and metrics derived from Portage Biotech's official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 3/31/2016 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2022 3/31/2023 3/31/2023 3/31/2024 3/31/2025 3/31/2026
DEI Shares Outstanding		 0.00 0.00 280,719,920.00 1,085,789,986.00 1,085,789,986.00 26,652,426.00 16,944,783.00 16,944,783.00 19,784,390.00 19,784,390.00 46,941,754.00
DEI Adjusted Shares Outstanding		 0.00 0.00 140,360.00 542,895.00 542,895.00 1,332,621.00 847,239.00 847,239.00 989,220.00 989,220.00 46,941,754.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 706.94 -4.76 -8.21 -12.66 -129.71 -129.71 -76.16 -6.84 -0.82
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% 98.96% 129,021.88% -102.92% -57.53% -159.28% -730.71% 0.00% 32.95% 90.55% -157.41%
EBIT Growth		 0.00% 98.96% 129,021.88% -102.92% -64.86% -147.76% -730.72% 0.00% 32.91% 90.51% -158.72%
NOPAT Growth		 0.00% -286.07% 91.01% 13.43% -116.28% -160.76% -6.33% 0.00% -10.12% 59.36% -211.35%
Net Income Growth		 0.00% 93.03% 19,404.37% -102.90% -101.70% -164.44% -446.02% 0.00% 27.98% 89.64% -158.82%
EPS Growth		 0.00% 400.00% 76,383.33% -101.20% 10.91% -163.27% -403.10% -1,899.85% 27.98% 92.65% 26.92%
Operating Cash Flow Growth		 0.00% 339.29% -107.68% 20.04% -770.86% -13.91% -1,354.33% -2.19% 24.64% 93.94% -209.39%
Free Cash Flow Firm Growth		 0.00% 0.00% 84.66% -3,601.62% 98.51% -365.76% 752.43% -18.69% -127.80% 81.37% -688.81%
Invested Capital Growth		 0.00% 0.00% 52,566.67% 8,808.29% -1.48% -0.79% -54.96% -102.73% 0.00% 0.00% 204.08%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 56.58% 100.00% 100.00% 111.37% 129.37% 85.43% 85.43% 87.72% 115.17% 52.33%
Interest Burden Percent		 100.00% 1,180.21% 99.98% 99.36% 109.16% 100.29% 99.83% 99.83% 104.36% 86.79% 191.09%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -1.08% 357.57% -4.54% -4.93% -13.07% -93.87% -265.91% 0.00% 944.38% -709.64%
Cash Return on Invested Capital (CROIC)		 0.00% -1,656,820.00% -481.62% -198.28% -1.51% -7.10% 64.16% 0.00% 0.00% 0.00% -818.13%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% -1.08% 357.57% -3.14% -3.29% -8.83% -74.72% -270.44% 0.00% 140.46% -885.15%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -1.08% 1,286.42% -3.61% -7.51% -18.90% -137.64% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.44 -25 -2.24 -1.93 -4.18 -11 -12 -12 -13 -5.19 -16
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% 81.25% 372.54% -20.94% -41.48% -97.16% -793.14% -1,008.33% 0.00% -313.46% -144.66%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -347.80% - 627.88% -245.07%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -9.20 -0.10 124 -3.62 -5.96 -15 -123 -123 -82 -7.81 -20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -9.20 -0.10 124 -3.62 -5.70 -15 -123 -123 -82 -7.78 -20
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.23 1.02 0.04 0.03 13.02 0.00 0.00 0.10
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.40 1.86 0.08 0.00 13.02 0.00 0.00 0.10
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.45 1.02 0.29 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.90 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.02 0.02 0.03 0.00 0.00 0.00 0.00 0.00 0.01
Long-Term Debt to Equity		 0.00 0.00 0.02 0.02 0.03 0.00 0.00 0.00 0.00 0.00 0.01
Financial Leverage		 0.00 -1.00 -0.98 -0.10 -0.05 -0.06 -0.11 -0.23 0.00 2.02 -0.98
Leverage Ratio		 0.00 1.01 1.01 1.16 1.18 1.19 1.23 1.36 0.00 -2.69 3.82
Compound Leverage Factor		 0.00 11.86 1.01 1.15 1.29 1.19 1.23 1.36 0.00 -2.34 7.30
Debt to Total Capital		 0.00% 0.30% 2.37% 2.41% 2.45% 0.10% 0.00% 0.21% 0.00% 0.00% 1.11%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.30% 2.37% 2.41% 2.45% 0.10% 0.00% 0.21% 0.00% 0.00% 1.11%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 32.11% 32.89% 31.24% -0.86% -20.77% 0.00% 85.13% -10.69%
Common Equity to Total Capital		 0.00% 99.70% 97.64% 65.48% 64.65% 68.66% 100.86% 120.56% 0.00% 14.87% 109.58%
Debt to EBITDA		 0.00 -1.89 0.00 -1.01 -0.64 -0.01 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 620.74 -0.07 2.16 1.22 0.68 0.00 0.04 0.00 0.00 0.02
Long-Term Debt to EBITDA		 0.00 -1.89 0.00 -1.01 -0.64 -0.01 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.01 -0.10 -1.89 -0.87 -0.01 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 2.40 3.60 4.03 1.67 0.92 0.00 0.43 0.00 0.00 0.03
Long-Term Debt to NOPAT		 0.00 -0.01 -0.10 -1.89 -0.87 -0.01 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 0.36 1.87 -0.48 -6.13 -87.33 0.00 -163.62 -24.28
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 30.90% 33.31% 32.49% 20.41% -1.71% 0.00% 85.13% -24.73%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.00 542.53 50.44 3.65 1.48 1.54 7.33 2.67 0.00 2.02 0.31
Quick Ratio		 0.00 541.95 49.80 3.44 1.23 0.86 5.89 2.67 0.00 1.52 0.04
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -25 -3.81 -141 -2.11 -9.81 64 52 -14 -2.70 -21
Operating Cash Flow to CapEx		 0.00% 0.00% -157.56% -124.71% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,717.40%
Free Cash Flow to Firm to Interest Expense		 0.00 -45.60 -158.83 -1,603.48 -3.78 -228.18 7,112.61 5,782.94 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 25.64 -44.71 -9.75 -13.41 -197.93 -13,753.11 -14,054.33 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 25.64 -73.08 -17.57 -13.41 -197.93 -13,753.11 -14,054.33 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 4.51 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 80.86 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 0.00 1.58 141 139 138 62 -1.69 0.00 -2.50 2.60
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 0.00 1.58 139 -2.08 -1.10 -76 -64 1.69 -2.50 5.10
Enterprise Value (EV)		 0.00 0.00 0.00 64 141 41 -11 47 0.00 6.78 -0.40
Market Capitalization		 0.00 0.00 0.00 22 99 4.38 2.62 52 10 9.15 0.72
Book Value per Share		 $0.00 $234.57 $3.59 $0.36 $0.09 $7.61 $4.49 $0.24 $0.00 ($0.01) $3.17
Tangible Book Value per Share		 $0.00 $234.57 $3.59 $0.20 $0.05 $4.36 ($0.33) $0.24 $0.00 ($0.01) $3.17
Total Capital		 0.00 60 9.85 152 149 148 75 3.34 0.00 -0.83 6.60
Total Debt		 0.00 0.18 0.23 3.66 3.66 0.15 0.00 0.01 0.00 0.00 0.07
Total Long-Term Debt		 0.00 0.18 0.23 3.66 3.66 0.15 0.00 0.01 0.00 0.00 0.07
Net Debt		 0.00 -60 -8.04 -7.81 -6.97 -10 -13 -5.02 0.00 -1.67 -0.41
Capital Expenditures (CapEx)		 0.00 0.00 0.68 0.69 0.00 0.00 0.00 0.00 0.00 0.00 1.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -0.05 -0.06 -1.41 -1.93 -1.03 1.27 -0.21 0.00 -0.55 -9.22
Debt-free Net Working Capital (DFNWC)		 0.00 59 7.47 4.76 1.23 1.74 12 4.82 0.00 1.13 -8.74
Net Working Capital (NWC)		 0.00 59 7.47 4.76 1.23 1.74 12 4.82 0.00 1.13 -8.74
Net Nonoperating Expense (NNE)		 2.76 -24 -126 1.66 3.06 8.26 93 93 63 2.62 4.05
Net Nonoperating Obligations (NNO)		 0.00 -60 -8.04 -7.81 -6.97 -10 -13 -5.02 0.00 -1.67 -3.93
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.27 0.00 0.00 0.00 0.05 0.04 0.19
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.46 $0.00 ($0.49) $0.00 $0.00 ($77.80) $0.00 ($5.72) ($4.18)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 280.72M 481.99K 10.95M 0.00 0.00 967.15K 0.00 1.18M 23.47M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.46 $0.00 ($0.49) $0.00 $0.00 ($77.80) $0.00 ($5.72) ($4.18)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 280.72M 481.99K 10.95M 0.00 0.00 967.15K 0.00 1.18M 23.47M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 280.72M 1.09B 10.95K 0.00 0.00 989.22K 0.00 0.00 23.47M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.44 -25 -1.56 -1.93 -4.18 -11 -12 -12 -13 -5.19 -16
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 -0.18 5,156.88 -41.10 -10.71 -343.58 -13,636.67 -13,636.67 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 -45.60 -93.13 -21.99 -7.51 -253.76 -1,289.17 -1,289.17 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 -0.18 5,128.50 -48.92 -10.71 -343.58 -13,636.67 -13,636.67 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 -45.60 -121.50 -29.80 -7.51 -253.76 -1,289.17 -1,289.17 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Portage Biotech

No quarterly metrics and ratios for Portage Biotech are available.


Financials Breakdown Chart

Portage Biotech Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Portage Biotech's financial year ends in March. Their financial year 2026 ended on March 31, 2026.

Portage Biotech's net income appears to be on an upward trend, with a most recent value of -$20.21 million in 2026, rising from -$9.20 million in 2016. The previous period was -$7.81 million in 2025. See Portage Biotech's forecast for analyst expectations on what's next for the company.

Portage Biotech's total operating income in 2026 was -$23.10 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $23 million

Over the last 10 years, Portage Biotech's total revenue changed from $0.00 in 2016 to $0.00 in 2026, a change of 0.0%.

Portage Biotech's total liabilities were at $13.01 million at the end of 2026, a 326.1% increase from 2025, and a 4,095.5% increase since 2017.

In the past 8 years, Portage Biotech's cash and equivalents has ranged from $159 thousand in 2017 to $10.55 million in 2022, and is currently $486 thousand as of their latest financial filing in 2026.

Over the last 10 years, Portage Biotech's book value per share changed from 0.00 in 2016 to 3.17 in 2026, a change of 317.3%.


Related Companies

Financial statements for NASDAQ:ALP last updated on 9/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Gold Explorer Sits Between Barrick’s Nevada Giants
Barrick Mining has spent decades building one of Nevada's richest gold districts, anchored by Fourmile, Goldru...
Wall Street Logic | Sponsoredtc pixel
Shocking AI prediction from the “Billionaire Whisperer"
Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...
Chaikin Analytics | Sponsoredtc pixel
This looks like plywood. It's not.
AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...
Eagle Publishing | Sponsoredtc pixel
The 2026 beginners Guide to Gold IRAs
Gold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...
Goldco Direct, LLC | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel
Elon Musk’s Hushed FCC Filing. Sept 25th.
Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...
Paradigm Press | Sponsoredtc pixel
American retirees will miss THIS. Big Banks just moved in.
Central banks spent nearly $130 billion on physical gold last year, on top of $145 billion the year before. Q1...
Cedar Gold Group | Sponsoredtc pixel